Bvf Inc Lexicon Pharmaceuticals, Inc. Transaction History

Bvf Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.3 - $3.58 $29.6 Million - $81.4 Million	-22,748,708 Reduced 93.1%	1,686,924 $4.05 Million
Q4 2023 Feb 14, 2024	BUY	$1.0 - $1.53 $4.44 Million - $6.79 Million	4,440,300 Added 22.21%	24,435,632 $37.4 Million
Q2 2023 Aug 14, 2023	BUY	$2.15 - $3.49 $8.27 Million - $13.4 Million	3,846,153 Added 23.82%	19,995,332 $45.8 Million
Q3 2022 Nov 14, 2022	BUY	$1.94 - $3.43 $3.88 Million - $6.86 Million	2,000,000 Added 14.14%	16,149,179 $38.8 Million
Q2 2022 Aug 15, 2022	SELL	$1.31 - $2.69 $271,707 - $557,932	-207,410 Reduced 1.44%	14,149,179 $26.3 Million
Q1 2022 May 16, 2022	SELL	$1.95 - $3.89 $6,651 - $13,268	-3,411 Reduced 0.02%	14,356,589 $30 Million
Q3 2021 Nov 15, 2021	BUY	$3.38 - $5.35 $20.2 Million - $31.9 Million	5,966,000 Added 71.07%	14,360,000 $69.1 Million
Q1 2021 May 17, 2021	SELL	$3.45 - $9.09 $8.86 Million - $23.4 Million	-2,569,000 Reduced 23.43%	8,394,000 $49.3 Million
Q4 2020 Feb 12, 2021	BUY	$1.05 - $3.67 $11.5 Million - $40.2 Million	10,963,000 New	10,963,000 $37.5 Million

141

238M

459K

133K

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $157M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.